All In Biotech

Drug Trial Radar · NCT02815592

Trial of BMS-986012 in Combination With Platinum and Etoposide

A Phase 1/2 Randomized Trial of BMS-986012 in Combination With Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Sep 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Nov 28, 2016

Primary completion

Dec 15, 2019

Study completion Aug 6, 2024

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jun 28, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this this study is to administer BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.

Conditions

  • Small Cell Lung Cancer

Interventions

  • BMS-986012Drug

  • CisplatinDrug

  • EtoposideDrug

  • PlatinumDrug

  • CarboplatinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs)Time frame: Cycle 1, Day 1 up to approximately 26 months.
  2. Number of participants with serious adverse events (SAEs )Time frame: Date of enrollment up to approximately 26 months.
  3. Discontinuations due to AEsTime frame: Cycle 1, Day 1 up to approximately 26 months.
  4. Number of participants who died due to AEsTime frame: Cycle 1, Day 1 up to approximately 26 months.
  5. Number of participants with laboratory toxicity grade shift from baselineTime frame: Cycle 1, Day 1 up to approximately 26 months.
  6. Progression Free SurvivalTime frame: From date of first dose or randomization until date of confirmed disease progression, up to 2 years

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Local Institution - 0002

    Barcelona, Spain

  • Local Institution - 0004

    Madrid, Spain

  • Local Institution - 0003

    Majadahonda - Madrid, Spain

  • Local Institution - 0010

    Málaga, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.